Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort.

Journal of Alzheimer's Disease : JAD
Graciela Muniz TerreraKaren Ritchie

Abstract

Alterations in Alzheimer's disease (AD) biomarkers have been observed decades before the onset of dementia. Cognitive dysfunction, while central to the clinical diagnosis of AD, has long been considered as a late-stage phenomenon. This assumption is currently challenged and signals on some cognitive tests are now being observed within the preclinical stage. As part of the European Prevention of Alzheimer's Dementia (EPAD) project, a battery of cognitive tests has been proposed (the EPAD Neuropsychological Examination, ENE) which is designed to detect cognitive changes in persons without clinical signs of AD but who are at high risk. Analysis of results from the 361 participants with complete measures and without dementia recruited into the EPAD Longitudinal Cohort Study showed that the majority have elevated biomarker levels, with significant associations between an episodic verbal memory task and tau, while amyloid-β (Aβ) was associated with a central executive task. These preliminary findings suggest that profiles of cognitive performance may be specific to a given biomarker, with a primarily hippocampal task being associated with higher levels of tau and a frontal executive task being associated with higher levels of Aβ. Whi...Continue Reading

References

Feb 1, 2011·Annals of Neurology·Victor L VillemagneChristopher C Rowe
Jul 13, 2012·Neurology·P Murali DoraiswamyUNKNOWN AV45-A11 Study Group
Sep 4, 2012·Neuropsychologia·Rebecca E AmariglioDorene M Rentz
Jan 11, 2013·Journal of Alzheimer's Disease : JAD·Kathryn A EllisUNKNOWN AIBL Research Group
Apr 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Cynthia M StonningtonEric M Reiman
Nov 2, 2013·Brain : a Journal of Neurology·Yen Ying LimUNKNOWN AIBL Research Group
Nov 26, 2013·Neurobiology of Aging·Sterling C JohnsonMark A Sager
Apr 22, 2014·Neurology·Elizabeth C MorminoUNKNOWN Harvard Aging Brain Study
Jan 7, 2015·Neurobiology of Aging·Yen Ying LimUNKNOWN Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Jan 30, 2015·JAMA Psychiatry·Robert H PietrzakUNKNOWN Australian Imaging, Biomarkers, and Lifestyle Research Group
Feb 24, 2015·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Zhuang SongMichael W Weiner
Dec 20, 2015·The Lancet. Psychiatry·Craig W RitchieUNKNOWN European Prevention of Alzheimer's Dementia (EPAD) Consortium
Oct 6, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Marion MortamaisKaren Ritchie
Oct 6, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Karen RitchieCraig W Ritchie
Jul 26, 2015·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Karen RitchieNikolaos Scarmeas
Aug 3, 2018·Neurology·Andrew J AschenbrennerJason J Hassenstab

❮ Previous
Next ❯

Citations

Jan 9, 2021·Brain and Cognition·Lou RizzoloFabienne Collette
Apr 4, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Silvia IngalaUNKNOWN EPAD consortium

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.